Fumagillin (high purity)
BVT-0424-M0011 mgCHF 90.00
BVT-0424-M0055 mgCHF 360.00
|Synonyms||Amebacilin; Fugilin; Fumidil; Fumadil B; NSC9168; U5762|
|Merck Index||14: 4286|
|Source/Host Chemicals||Isolated from Aspergillus fumigatus (Strain WDMH-35).|
|Purity Chemicals||≥98% (NMR)|
|Solubility||Soluble in DMSO, acetone or chloroform. Slightly soluble in methanol or ethanol. Insoluble in water.|
|Identity||Determined by 1H-NMR and MS.|
|Declaration||Manufactured by BioViotica.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Protect from light.|
Stable for at least 2 years after receipt when stored at -20°C.
Store solutions at -20°C in the dark.
|Product Specification Sheet|
- Meroterpenoid antibiotic.
- Anticancer, antimicrobial, antimalarial and amoebicidal compound. Potent, selective and covalent inhibitor of methionine aminopeptidase-2 (MetAP2).
- Anti-angiogenic by impairing the growth of endothelial cells and altering gene expression.
- Inhibits endothelial cell proliferation in vitro and tumor-induced angiogenesis in vivo.
- Suppresses the HIV-1 infection of human macrophages through the inhibition of HIV-1 viral protein R (Vpr) activity.
- Inhibits neovascularization and might be useful in non-tumor diseases such as diabetic retinopathy, arthritis and psoriasis, which involve neovascularisation processes.
- Reduces diet-induced adipose tissue formation in mice, independent of its effects on angiogenesis.
- Antibiotic substance produced by Aspergillus fumigatus: T.E. Eble, et al.; Antibiot. Chemother. 1, 54 (1951)
- Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth: D. Ingber, et al.; Nature 348, 555 (1990)
- The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2: N. Sin, et al.; PNAS 94, 6099 (1997)
- Inhibition of Angiogenesis In Vivo by ets-1 Antisense Oligonucleotides-Inhibition of Ets-1 Transcription Factor Expression by the Antibiotic Fumagillin: N. Wernert, et al.; Angew. Chem. Int. Ed. Engl. 38, 3228 (1999)
- Structure elucidation of fumagillin-related natural products: J. Halasz, et al.; Tetrahedron 56, 10081 (2000)
- A re-evaluation of fumagillin selectivity towards endothelial cells: S. Rodriguez-Nieto, et al.; Anticancer Res. 21, 3457 (2001)
- Fumagillin treatment of intestinal microsporidiosis: J. Molina, et al.; N. Engl. J. Med. 346, 1963 (2002)
- Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells: C.M. Mazzanti, et al.; Genome Res. 14, 1585 (2004)
- Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of Vpr activity: N. Watanabe, et al.; FEBS Lett. 580, 2598 (2006)
- Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors: B. Lefkove, et al.; Expert Rev. Anti-Infect. Ther. 5, 573 (2007)
- Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo: X. Chen, et al.; Chem. Biol. 16, 193 (2009)
- Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis: L. Hou, et al.; Pathol. Int. 59, 448 (2009)
- Syntheses of fumagillin and ovalicin: J. Yamaguchi & Y. Hayashi; Chem. Eur. J. 16, 3884 (2010)
- Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity: H.R. Lijnen, et al.; Obesity 18, 2241 (2010)
- Inhibition of neutrophil function following exposure to the Aspergillus fumigatus toxin fumagillin: J.P. Fallon, et al.; J. Med. Microbiol. 59, 625 (2010)
- Fumagillin and structurally related molecules as source of new drugs: D. Gamba-Sanches; Mini-Rev. Org. Chem. 9, 126 (2012)
- Stimulation of suicidal erythrocyte death by fumagillin: M. Zbidah, et al.; Basic Clin. Pharmacol. Toxicol. 112, 346 (2013)